



**HAL**  
open science

## Hepatitis D virus interferes with hepatitis B virus RNA production via interferon-dependent and -independent mechanisms

Julie Lucifora, Dulce Alfaiate, Caroline Pons, Maud Michelet, Ricardo Ramirez, Floriane Fusil, Fouzia Amirache, Axel Rossi, Anne-Flore Legrand, Emilie Charles, et al.

### ► To cite this version:

Julie Lucifora, Dulce Alfaiate, Caroline Pons, Maud Michelet, Ricardo Ramirez, et al.. Hepatitis D virus interferes with hepatitis B virus RNA production via interferon-dependent and -independent mechanisms. *Journal of Hepatology*, In press, 10.1016/j.jhep.2023.01.005 . hal-03992721

**HAL Id: hal-03992721**

**<https://hal.science/hal-03992721>**

Submitted on 16 Feb 2023

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1 **Interferon-dependent and independent mechanisms drive**  
2 **Hepatitis Delta Virus interference on Hepatitis B Virus RNA production**  
3

4  
5 Julie Lucifora<sup>1,2#</sup>, Dulce Alfaiate<sup>2#,3</sup>, Caroline Pons<sup>1,2#</sup>, Maud Michelet<sup>2</sup>, Ricardo Ramirez<sup>4</sup>,  
6 Floriane Fusil<sup>1</sup>, Fouzia Amirache<sup>1</sup>, Axel Rossi<sup>5</sup>, Anne-Flore Legrand<sup>1</sup>, Emilie Charles<sup>1</sup>, Serena  
7 Vegna<sup>2</sup>, Rayan Farhat<sup>2</sup>, Michel Rivoire<sup>6</sup>, Guillaume Passot<sup>7</sup>, Nicolas Gadot<sup>6</sup>, Barbara Testoni<sup>2</sup>,  
8 Charlotte Bach<sup>8</sup>, Thomas F. Baumert<sup>8,9</sup>, Anastasia Hyrina<sup>3</sup>, Rudolf K. Beran<sup>3</sup>, Fabien Zoulim<sup>2,10</sup>,  
9 Andre Boonstra<sup>11</sup>, Hildegard Büning<sup>5</sup>, Eloi R. Verrier<sup>8</sup>, François-Loïc Cosset<sup>1</sup>, Simon P. Fletcher<sup>4</sup>,  
10 Anna Salvetti<sup>1,2#,\*</sup> and David Durantel<sup>1,2#,\*</sup>  
11  
12  
13  
14

15 <sup>1</sup> CIRI, Centre International de Recherche en Infectiologie, Univ Lyon, Inserm, U1111,  
16 Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, F-69007, Lyon, France.

17 <sup>2</sup>INSERM, U1052, Cancer Research Center of Lyon (CRCL), University of Lyon (UCBL1), CNRS  
18 UMR\_5286, Centre Léon Bérard, Lyon, France (past affiliation when # indicated)

19 <sup>3</sup>Service des Maladies Infectieuses et Tropicales, Hôpital de la Croix-Rousse, Hospices Civils  
20 de Lyon, Lyon, France  
21

22 <sup>4</sup>Gilead Sciences, Inc., Foster City, CA, USA

23 <sup>5</sup>Institute of Experimental Hematology, Hannover Medical School, Hannover, Germany

24 <sup>6</sup>Centre Léon Bérard (CLB), INSERM, U1032, Lyon, France

25 <sup>7</sup> Service de chirurgie générale et oncologique, Hôpital Lyon Sud, Hospices Civils de Lyon Et  
26 CICY, EA3738, université Lyon 1

27 <sup>8</sup>Université de Strasbourg, Inserm, Institut de Recherche sur les Maladies Virales et Hépatiques  
28 UMR\_S1110, Strasbourg, France

29 <sup>9</sup>Institut Hospitalo-Universitaire, Pôle Hépato-digestif, Nouvel Hôpital Civil, 67000 Strasbourg,  
30 France.  
31

32 <sup>10</sup>Department of Hepatology, Croix-Rousse Hospital, Hospices Civils de Lyon, Lyon, France

33 <sup>11</sup>Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center  
34 Rotterdam, Gravendijkwal 230, Rotterdam, The Netherlands.

35 \*equal contribution  
36  
37  
38  
39

40  
41 **Correspondence**

42 Dr. Julie Lucifora

43 [julie.lucifora@inserm.fr](mailto:julie.lucifora@inserm.fr) ; CIRI – 21 avenue Tony Garnier 69007 LYON, FRANCE  
44  
45

46 **Key Words**

47 Hepatitis Delta virus; Hepatitis B virus; interference, interferon  
48  
49

50 **List of abbreviations**

51 AAV, adeno-associated virus;

52 cccDNA, covalently closed circular DNA;

53 CHIP, chromatin immunoprecipitation;

54 dpi, days post-infection;

55 HDag: HDV antigens;

56 HBV, Hepatitis B virus;

57 HCV, Hepatitis C virus;  
58  
59  
60  
61  
62  
63  
64  
65

1 HDV, hepatitis Delta virus;  
2 HDAg, HDV antigens;  
3 HuHep mice, liver humanized mice i.e mice with human hepatocytes;  
4 IFN, interferon;  
5 ISG, interferon-stimulated gene;  
6 LHD, large hepatitis delta antigen;  
7 moi, multiplicity of infection;  
8 rcDNA relaxed circular DNA;  
9 pgRNA, pregenomic RNA;  
10 PHH, primary human hepatocyte;  
11 RIP, RNA immunoprecipitation;  
12 SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2;  
13 SHD, small hepatitis delta antigen;  
14 wpi, weeks post-infection.

### 19 Author contributions

- 20 - study concept and design: JL, DD, AS
- 21 - acquisition of data: JL, DA, CP, MM, FF, FA, AR, AFL, EC, SV, RF, CB
- 22 - analyses and interpretation of data: JL, RR, ERV, AS, DD
- 23 - drafting of the manuscript: JL
- 24 - funding acquisition: JL, ERV, TFB, AS, DD
- 25 - material support: MR, EV, AH, RB, FZ, AB, HB, FLC, SF, GP, NG

### 29 Financial support

30 This work was supported by grants from the ANRS (French national agency for research on  
31 AIDS and viral hepatitis, CSS12, ECTZ33708, ECTZ102776, ECTZ104527, ECTZ119828,  
32 ECTZ123278, ECTZ73912 & ECTZ77934) as well as financial support of INSERM. DA was  
33 supported by PhD scholarships from Fundação Calouste Gulbenkian and Fundação para a  
34 Ciência e a Tecnologia. JL received an award from the Gilead Sciences International Research  
35 Scholars Program in Liver Disease. EV and TB received a grant from ANR/FRM for work on  
36 SARS-Cov2 (Fondation pour la Recherche Médicale, grant TargEnt). TFB acknowledges funding  
37 through ERC AdG 671231 and ANR-IHU TheraHCC2 IHU201901299 and Inserm Plan Cancer.  
38 This work has been published under the framework of the LabEx DevWeCan and LABEX [ANR-  
39 10-LABX-0028\_HEPSYS] and benefits from a funding from the state managed by the French  
40 National Research Agency as part of the Investments for the future program.

### 47 Acknowledgements

48 The authors would like to thank Laura Dimier, Jennifer Molle, Océane Floriot, Anaëlle Dubois  
49 and Sarah Heintz (CRCL) for help with the isolation of primary human hepatocytes, as well as  
50 the staff from Prof Michel Rivoire's and Dr Guillaume Passot's surgery room (CLB) for providing  
51 us with liver resections. We thank Prof Siddiqui for the kind gift of the plasmids expressing  
52 mutated versions of the epsilon loop of HBV RNAs. We thank Marine Oudot et Sarah C. Durand  
53 (Inserm U1110, Strasbourg) for their support with staining of the *in vivo* samples as well as  
54 and Dr Florian Wrensch (Inserm U1110, Strasbourg) for his support with SARS-CoV-2 infection.  
55 The following reagent was obtained through BEI Resources, NIAID, NIH: SARS-Related  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 Coronavirus 2, Isolate hCoV-19/USA/PHC658/2021 (Lineage B.1.617.2; Delta Variant), NR-  
2 55611, contributed by Dr. Richard Webby and Dr. Anami Patel.  
3

4 **Competing financial interest**

5 JL and DD received a research grant from Gilead Sciences to perform experiments. RR, AH,  
6 RKB and SPF are employees of Gilead Sciences, Inc.  
7

8 **Data Availability Statement**

9  
10 The data presented in this manuscript are available through the corresponding author (Julie  
11 Lucifora) upon reasonable request.  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

## Abstract

**Background & Aims.** Chronic co-infection with hepatitis B and D viruses (HBV and HDV) leads to the most aggressive form of chronic viral hepatitis. Here, we aimed at elucidating the molecular mechanisms leading to the interference of HDV on HBV observed in most co-infected patients.

**Methods.** Patient liver tissues, primary human hepatocytes, HepaRG cells and human liver chimeric mice were used to analyze the effect of HDV on HBV using virological and RNA-seq analyses, as well as RNA synthesis, stability and association assays.

**Results.** Transcriptomic analyses in cell culture and mouse models of co-infection allowed to define the HDV-induced signature mainly composed of interferon (IFN)-stimulated genes (ISGs). We also provide evidence that ISGs are upregulated in HDV-HBV chronically infected patients but not in cells only expressing the HDV antigens (HDAg). Inhibition of the hepatocyte IFN response partially rescued the levels of HBV parameters. We observed less HBV RNAs synthesis upon HDV infection or HDV protein expression. Additionally, HDV infection or expression of HDAg alone specifically accelerated the decay of HBV RNAs and HDAg are associated with HBV RNAs. On the contrary, HDAg expression did not affect other viruses such as hepatitis C virus (HCV) or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

**Conclusions.** Our data indicate that HDV interferes with HBV through both IFN-dependent and IFN-independent mechanisms. Specifically, we uncover a new viral interference mechanism in which proteins of a satellite virus affect RNA production of its helper virus. Exploiting these finding could pave the way to the development of new therapeutic strategies against HBV.

## Impact and implications

Although, the molecular mechanisms remained unexplored, it was known for long that despite its dependency, HDV decreased HBV viremia in patients. Here, using *in vitro* and *in vivo* models, we showed that HDV interferes with HBV through both IFN-dependent and IFN-independent mechanisms affecting HBV RNAs metabolism and we defined the HDV-induced modulation signature. The mechanisms we uncovered could pave the way to the development of new therapeutic strategies against HBV by mimicking and/or increasing the effect of HDAg on HBV RNAs and the HDV-induced modulation signature may allow to the draw correlation

withthe responsiveness to IFN alpha treatment and thereby ultimately help in the management of HBV/HDV co-infected patients.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

## Introduction

1  
2  
3  
4 Hepatitis B Virus (HBV) functionally persists in the nucleus of hepatocytes as a non-integrated,  
5 episomal DNA, the so-called covalently closed circular DNA (cccDNA) that serves as template  
6 for transcription of all HBV RNAs by the cellular RNA polymerase II (RNA Pol-II). It thereby  
7 drives production of viral RNAs, antigens (HBeAg and HBsAg), and progeny virions (containing  
8 a partially double-stranded relaxed circular DNA (rcDNA) that results from reverse  
9 transcription of a pregenomic RNA (pgRNA) within assembled nucleocapsid). CccDNA is  
10 organized into a chromatin-like structure that displays the typical beads-on-a-string  
11 arrangement in electron microscopy [1, 2]. Viral proteins (HBx, HBc), host histones but also  
12 non-histone cellular proteins are directly or indirectly bound to cccDNA [3-5] and its  
13 transcriptional activity is subjected to epigenetic regulations [4, 6, 7]. As an example, the  
14 recruitment of H3 and H4 histones, as well as of several cellular transcription factors and  
15 histone modifying enzymes has been shown to modulate cccDNA transcriptional activity [4, 6,  
16 8]. Hepatitis Delta Virus (HDV) contains a ribonucleoprotein composed of a circular single-  
17 stranded negative RNA genome, presenting a “quasi” double-stranded conformation, coated  
18 with both small and large isoforms of the HDV antigen (HDAg). HDV is a defective satellite  
19 virus that uses the envelope of HBV [9] to egress from and to re-enter into hepatocytes. Apart  
20 from those steps, HDV intracellular RNA replication is thought to be independent of HBV. In  
21 the nucleus of HDV-infected cells, incoming HDV genomes serve as templates for the synthesis  
22 of replicative intermediates called anti-genomes, as well as for HDV mRNAs transcription by  
23 the RNA Pol II [10, 11]. Two isoforms of HDAg are produced upon the HDV life cycle: S-HDAg  
24 and L-HDAg that are essential for replication and secretion, respectively (see [12] for review).

25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47 HDV co-infection has been shown to reduce HBV replication in the majority of HBV/HDV co-  
48 infected patients as well as in different animal models [9, 13-22]. A cross-sectional study in a  
49 small cohort of HBV/HDV infected patients reported HDV dominance in 75% of the cases [23].  
50 There is limited understanding of how HDV interferes with HBV. Interference is thought to be  
51 independent of adaptive immunity since it was also observed in isolated hepatocytes in the  
52 absence of immune cells [24, 25]. Overexpression models suggested that both forms of HDAg  
53 might inhibit HBV replication by repressing the HBV enhancer activity [26]. Alternatively, we  
54 found that the levels of HBV RNAs, but not of cccDNA, were decreased in the presence of HDV  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 in non-transformed and immune-competent hepatocytes infected *in vitro*, suggesting an HDV-  
2 induced inhibition of HBV RNAs transcription or stability [24]. Here, we aimed to better  
3 characterize the mechanism(s) underlying interference of HDV on HBV using highly relevant  
4 infection models including primary human hepatocytes (PHH), differentiated HepaRG cells  
5 (dHepaRG), liver chimeric humanized mouse model (HuHep) as well as patient liver tissues. In  
6 addition to advance our current knowledge on the interplay between a satellite virus and its  
7 helper virus, these data may help identifying new antiviral targets for treatment of both  
8 viruses.  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

## Results

1  
2  
3  
4 **HDV infection impairs HBV replication *in vivo* and *in vitro*.** We previously reported that super-  
5 infection of HBV-infected differentiated HepaRG cells with HDV results in lower levels of HBV  
6 replication [24] similarly to what was previously described in HDV-infected patients [16-21].  
7 We confirmed an interference of HDV on HBV in a co-infection setting *in vitro* using dHepaRG  
8 cells and PHH, in which a decrease in intracellular HBV RNAs as well as secreted HBeAg and  
9 HBsAg, but not cccDNA, in co-infected vs. HBV mono-infected cells was observed (**Figure 1A,**  
10 **1B and S1**). Northern blot analyses showed that the levels of all detectable HBV RNA species  
11 are affected by HDV co-infection (**Figure 1A, 1B**). On the contrary, the presence of HBV had  
12 no impact on the level and kinetics of intracellular HDV replication (**Figure S1**, left panels) and  
13 no cell toxicity (measured by LDH release in cells supernatants) was observed in the presence  
14 of HDV (**Figure S2**). To further confirm the interference of HDV on HBV *in vivo* and extend the  
15 data published in uPa-SCID mice reporting a decreased HBV viremia in the presence of HDV  
16 [15], FRG liver humanized mice (HuHep) were either infected with HBV alone (HBV), co-  
17 infected with HBV and HDV (HBV + HDV) or infected with HBV first and then super-infected  
18 with HDV, four weeks later (HBV->HDV). Except for the levels of cccDNA, all the other HBV  
19 replication parameters, including intrahepatic HBV DNA, viremia and the two secreted viral  
20 antigens (HBeAg and HBsAg) decreased in the presence of HDV (**Figure 1C**). The interference  
21 of HDV on HBV was more pronounced in the co-infection setting compared to the super-  
22 infection setting (**Figure 1C**). Interestingly, in each individual super-infected mouse, the peaks  
23 of HDV RNA correlated with a decrease in HBV parameters (**Figure S3**). Using dHepaRG cells  
24 with an integrated HBV genome or HBV-infected HuHep mice, we observed that HDV also  
25 interfered with other HBV genotypes (C and E) than HBV genotype D (mainly used in our study)  
26 (**Figure S4**).

27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50 **Identification of the HDV-induced signature.** We and others did show that, in contrast to HBV  
51 genotype D, HDV genotype 1 induced a strong increase in mRNA levels of classical interferon  
52 (IFN) stimulated genes (ISGs), such as MX1, OAS1 or RSAD2 [24, 26, 27]. We further confirmed  
53 these observations in HDV-infected PHH, from three different donors, in which induction of  
54 the RSAD2 (coding for Viperin) ISG occurred concomitantly to HDV replication (**Figure S5A,**  
55 **S1**). To identify host factors consistently modulated by HDV in an unbiased approach, we  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 performed RNA sequencing analyses of samples from dHepaRG or PHH infected with HDV  
2 and/or HBV (co-infections or mono-infection), as well as liver samples from infected HuHep  
3 mice. First, we confirmed that HBV did not induce strong transcriptional modulations *in vitro*  
4 [28] since no significant changes in the levels of any cellular RNA were observed in HBV  
5 infected cells at day six post-infection (**Figure 2**). Conversely, HDV induced strong changes in  
6 the levels of cellular mRNAs (**Figure 2**) in dHepaRH and PHH that were similar whether HBV  
7 was present or not (**Figure 2**). Pathway analyses revealed that innate-immune related  
8 pathways, and notably the IFN pathway, are consistently up-regulated upon HDV infection  
9 (**Figure 2A**) and that most of the significant HDV-induced genes in dHepaRG and PHH were  
10 also induced following a 24h treatment with IFN- $\alpha$  (non-infected cells, **Figure S5B**). We  
11 identified a subset of 73 ISGs that were significantly up-regulated across the three models that  
12 likely represent a “HDV signature” of virus-induced perturbations (**Figure 2B**). Since RSAD2  
13 was among the most up-regulated genes in HDV-infected hepatocytes, it was used as a  
14 biomarker of the HDV-induced IFN pathway throughout the rest of the study. Interestingly, a  
15 similar modulation of IFN-related genes was observed in patients. Despite a generally more  
16 advanced liver disease in HBV mono-infected patients in our cohort (**Table1**), possibly  
17 suggesting a higher level of inflammation, IFN-related genes were more strongly induced in  
18 HBV-HDV co-infected patients (**Figure 2A**). Notably, a set of ISGs that was the most strongly  
19 induced by HDV in cells and mice was found significantly and specifically associated to HDV  
20 co-infection in patients, such as MX1, RSAD2, IFITM1, OASL, IFIT3, and IFI27 (**Figure 2B**).

21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41 **The HDV-induced IFN response is partially responsible for the interference on HBV.** Since  
42 some genes up-regulated by HDV have been previously described to be capable of inhibiting  
43 HBV (**Figure 2**), we hypothesized that the interference of HDV on HBV could be due to its  
44 capacity to induce the IFN pathway. We therefore performed a series of experiments to  
45 analyze HBV parameters in the absence of the HDV-induced IFN pathway. First, we used TPCA-  
46 1, a chemical inhibitor of the IKKb and IFN pathways [29]. In a co-infection setting and in the  
47 presence of TPCA-1, the induction of the IFN pathway by HDV (measured here by RSAD2 and  
48 MxA expression) was markedly reduced (**Figure 3A, S6A**) and we observed a partial rescue of  
49 the levels of secreted HBV antigens and particles as well as intracellular HBV RNAs (**Figure 3B,**  
50 **S6A**). We confirmed these data using JAK1 inhibitors (**Figure S6B, S6C**). Second, as MDA5 has  
51 been described to be the cellular receptor responsible for HDV recognition and induction of  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 the IFN pathway in hepatocytes [30], we generated an MDA5 knock-out (KO) HepaRG cell line  
2 using a CRISPR/Cas9 approach and IRF3<sub>KO</sub> cell line to block intracellular induction of ISGs. We  
3 also generated a Cas9 control (CTL) cell line as well as a RIG-I<sub>KO</sub> control cell line (RIG-I not being  
4 involved in the HDV-induced IFN pathway) [30]. As RIG-I and MDA5 are almost not detectable  
5 at basal levels, treatment with poly(I:C) or IFN- $\alpha$  (**Figure S7A**) as well as infection with HDV  
6 (**Figure S7B**) were performed to confirm the knock-out phenotype of the different cell lines.  
7 Moreover, even though differences in viral replications were probably due to their  
8 differentiation status, all cell lines were still susceptible to both HBV and HDV infections  
9 (**Figure 4A**) and exogenous IFN- $\alpha$  was also still efficient to inhibit both viruses in all the cell  
10 lines (**Figure S7C**). As expected, HDV did not induce any response in dHepaRG-Cas9-MDA5<sub>KO</sub>  
11 [30], but also not in dHepaRG-Cas9-IRF3<sub>KO</sub> cells, whereas it did induce ISGs in both dHepaRG-  
12 Cas9-CTL and dHepaRG-Cas9-RIG-I<sub>KO</sub> cells (**Figures 4B, 4C**). Again, we observed a partial rescue  
13 of the levels of HBV parameters in all the cells that displayed a lack of HDV-induced IFN  
14 response (**Figure 4D, 4E, 4F**). Of note, levels of HDV RNAs and proteins are only slightly  
15 increased in dHepaRG-Cas9-MDA5<sub>KO</sub> compared to dHepaRG-Cas9-RIG-I<sub>KO</sub> cells and kinetics of  
16 appearance and decrease are similar (**Figure S7D**). Altogether, our results show that the  
17 induction of the IFN pathway by HDV is only partially responsible for the inhibition of HBV and  
18 suggest that HDV itself may play a direct role, independent of the IFN response, likely through  
19 its proteins as previously documented [26].  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38

39 **HDV proteins expression does not induce an IFN response but specifically reduces HBV in**  
40 **cell-based models.** We next addressed the direct role of HDV proteins in the interference of  
41 HDV on HBV. In dHepaRG cells either stably producing S-HDAg and L-HDAg in a Tet-inducible  
42 manner or transduced with recombinant AAV vectors expressing these genes (AAV-SHD and  
43 AAV-LD), the two viral proteins were mainly expressed in hepatocytes, exclusively located in  
44 the nucleus (**Figure S8A, S9A**) and did not induce an IFN response as shown by the absence of  
45 RSAD-2 and RIG-I expression modulation (**Figure S8B, S8C, S9B, S9C**). Of note, probably due  
46 to a leak in the inducible system, the HepaRG-TR-LHD cells that expressed low but detectable  
47 levels of L-HDAg in the absence of Tet (**Figure S8B**), could not be productively infected by HDV  
48 as evidenced by a lack of detection of S-HDAg (**Figure S8B, HBV+HDV condition**) and RSAD2  
49 induction (**Figure S8C, HBV+HDV condition**), confirming data from previous studies suggesting  
50 that even low levels of L-HDAg expression have a negative trans-dominant effect on HDV  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 replication [31, 32]. We transduced HBV-infected dHepaRG cells or HuH7.5-NTCP cells with  
2 AAV-SHD and AAV-LHD vectors (**Figure 5A, S10A**) and observed a decrease of the levels of HBV  
3 RNAs and secreted HBV antigens (**Figure 5B, S10B**) without induction of ISGs (**Figure 5B, S8B,**  
4 **S8C, S9B, S9C**) or profound modulations in the levels of HNF4a, a transcription factor crucial  
5 for the synthesis of HBV RNAs (**Figure 5B**). Importantly, expression of S-HDAg or L-HDAg had  
6 no effect on the levels of intracellular RNAs for other viruses such as hepatitis C virus (HCV) or  
7 SARS-Cov2 (**Figure S10C, S11**) strongly suggesting a specific phenotype on HBV. Of note, we  
8 already reported rather low rates of HBV/HDV co-positive cells [24] and confirmed that with  
9 liver slices from co-infected HuHep mice (**Figure S12A**) as also already reported by others [27].  
10 To exclude the involvement of secreted cellular factors (unrelated to the IFN response)  
11 following HDV infection/HDAg expression that could act in cis or trans, HBV-infected dHepaRG  
12 cells were treated with fresh undiluted media from cells transduced with AAV-SHD or AAV-  
13 LHD (that do not induce an IFN response) and we did not observe any reduction in HBV  
14 parameters (**Figure S12B**) strongly suggesting that HBV/HDV co-infection of the same cells is  
15 needed for the interference of HDAg on HBV.  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30

31 **HDV decreases the level of nascent HBV RNAs and their stability.** The decrease in HBV RNAs  
32 observed with no effect on cccDNA amounts suggests that HDV may affect either HBV RNAs  
33 transcription and/or stability. We thus performed run-on and RNA stability assays to test these  
34 hypotheses. We first confirmed the specificity of both assays using RG7834, a molecule known  
35 to decrease the levels of HBV RNAs (**Figure 6A**) [33] without affecting their synthesis (**Figure**  
36 **6B, 6C**) but by reducing their stability (**Figure 6D, 6E**) [33], and IFN- $\alpha$ , known to affect both  
37 HBV RNAs synthesis (**Figure 6B, 6C**) and stability (**Figure 6D**) [34]. We observed a decrease in  
38 the levels of nascent HBV RNAs in dHepaRG cells co-infected with HDV or transduced with  
39 AAV-SHD and AAV-LHD (**Figure 6B, 6C**) without any significant effect on the levels of nascent  
40 cellular *PRNP* mRNAs (**Figure S13A**). In addition, with RNA stability assays performed in PHH  
41 (because transcription inhibitors were toxic in dHepaRG cells), we observed a faster decrease  
42 in the level of HBV RNAs when cells were co-infected with HDV or transduced with AAV-SHD  
43 and AAV-LHD (**Figure 6D, 6E**). Of note, the stability of the cellular *PRNP* mRNAs was not  
44 affected by any of the infection/transduction/treatment (**Figure S13B, S13C**). Altogether,  
45 these data strongly suggest that HDV/HDAg expression interfere with RNAs production. It has  
46 been proposed that m6A modifications induced within the 3' epsilon stem loop of HBV  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 transcripts controls their stability [35]. However, we observed a similar decrease in the levels  
2 of HBV RNAs upon transduction with the AAV-SHD and AAV-LHD vectors in cells transfected  
3 with plasmids encoding a wild type HBV genome or a mutated HBV genome that abrogate the  
4 m6A site of the epsilon loop of HBV RNAs (**Figure S14**).  
5  
6  
7  
8

9 **HDV proteins interact with HBV RNAs.** We hypothesized that HDAg might be associated to  
10 the HBV mini-chromosome and/or RNAs derived from its transcription and may thereby  
11 influence RNA production. To test this hypothesis, we set up a protocol to be able to  
12 determine in one sample 1) the efficiency of the immunoprecipitation by western blot  
13 analyses, 2) the association of a given protein (i.e., RNA Pol-II or HDAg for instance) to cccDNA  
14 by qPCR analyses, as well as 3) the association of a given protein (i.e., RNA Pol-II or HDAg for  
15 instance) to HDV RNAs (as controls since these proteins are known to associate to HDV RNAs)  
16 or HBV RNAs by RT-qPCR analyses. Western blot analyses after immunoprecipitations (IPs) of  
17 cross-linked samples from HBV/HDV co-infected PHH, dHepaRG and HuHep mice showed  
18 efficient IPs of both HDAg and RNA Pol-II (**Figure 7A, 7B, 7C, blots on the left**). RNA extractions  
19 followed by RT-qPCR to detect HDV RNAs after IPs, validated our methods since we found an  
20 association of HDAg and RNA Pol-II to HDV RNAs (**Figure 7A, 7B, 7C, HDV RNAs after IP**). DNA  
21 extractions followed by specific qPCR for cccDNA detection after IPs showed no association of  
22 HDAg to cccDNA in the presence of HDV in PHH and dHepaRG cells (**Figure 7A, 7B, cccDNA**  
23 **after IP**) and we observed a positive signal in only one of the HuHep mouse tested (**Figure 7C,**  
24 **cccDNA after IP**). Of note, we did not observe modifications of the amount of HBc, acetylated  
25 histone H3 (H3K27) or RNA Pol-II associated to cccDNA in the presence of HDV (**Figure S15A**).  
26 As phosphorylation of serine 2 and 5 of RNA Pol-II is a key feature for its transcriptional  
27 activity, we performed additional immunoprecipitation assays and did not observe  
28 modifications of the phosphorylation of serine 2 and 5 of the cccDNA-bound RNA Pol-II (**Figure**  
29 **S15B**). Interestingly, RT-qPCR to detect HBV RNAs after IPs revealed an association of HDAg to  
30 HBV RNAs in *in vitro* as well as *in vivo* samples (**Figure 7A, 7B, 7C, HBV RNAs after IP**). Using  
31 AAV-SHD and AAV-LHD vectors or dHepaRG-TR-SHD and dHepaRG-TR-LHD cells, we further  
32 showed that both S-HDAg and L-HDAg are associated to HBV RNAs in HBV-infected dHepaRG  
33 cells (**Figure 7D, S16**). We also tested the association of HDAg to the cellular *PRNP* mRNAs and  
34 did not observe any positive signal by RT-qPCR after IPs with anti-HDAg antibodies (**Figure**  
35 **S17**), suggesting that HDAg does not associate to any random RNA in the cells. Even though  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 the amount of RNAs recovered after IPs was lower with cells that were cross-linked with UV  
2 (compared to formaldehyde cross-linking) (**Figure S18A**), we still observed an association of  
3 HDAg with HBV RNAs (**Figure S18B**) suggesting a direct interaction of HDAg with HBV RNAs.  
4  
5  
6  
7  
8

## 9 **Discussion**

10  
11  
12 Although the inhibitory phenotype is observed in a majority of co-infected patients [23], the  
13 mechanism underlying the interference of HDV on HBV replication remained unclear. We  
14 previously showed that it is independent of adaptive immunity since it was observed *in vitro*  
15 in HBV-infected hepatocytes super-infected by HDV [24]. Using various cell culture models as  
16 well as liver-humanized mice, we extend here our initial observations by showing that this  
17 phenomenon can also occur in co-infection settings. Additionally, our data suggest that this is  
18 specific for HBV and HDV since neither HCV [36] nor SARS-Cov2 [37] RNAs levels were found  
19 to be affected by HDV expression. Cell culture assays as well as experiments with mice [24,  
20 26, 27, 30, 38-41], already showed that HDV induces a strong innate response with an increase  
21 of mRNA levels of classical interferon ISGs, such as MX1, OAS1 or RSAD2. Here, we confirm  
22 this result and define an HDV-induced modulation signature by performing RNA sequencing  
23 analyses with samples from the most relevant *in vitro* and *in vivo* models. Notably, we confirm  
24 the relevance of this signature in an exploratory cohort of patients. Although the number of  
25 patients is low and the levels of inflammation complicates the analysis of innate immune-  
26 related gene expression, we believe that the HDV signature we characterized in infection  
27 models may reflect the specific response to HDV infection in patients. The data should be  
28 confirmed by single-cell RNAseq (to exclude the contribution of immune cells and high  
29 inflammation levels) in a larger cohort of patients (with a careful matching of potential  
30 confounders as fibrosis and inflammatory activity, as well as HBV and HDV replicative activity)  
31 to address if this “pan-model” signature would be relevant for the clinical management of  
32 chronic HDV infection. Indeed, a poor response of HCV-infected patients to IFN- $\alpha$ -based  
33 treatments was related to basal up-regulation of ISGs expression, as well as a particular  
34 polymorphism of the IL28b gene [42, 43]. Therefore, the analysis of the baseline (i.e. before  
35 an IFN-based treatment is started) expression profiles of human HDV-infected samples might  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 provide information to investigate underlying mechanisms and find biomarkers of IFN- $\alpha$   
2 treatment failure/success.  
3  
4

5 In contrast to what previously reported in transformed cells (HuH7) [26], the over-expression  
6 of S-HDAg or L-HDAg alone in either dHepaRG or PHH did not induce an IFN response,  
7 suggesting that HDV genomic/antigenomic RNA amplification was the sole driver of the IFN  
8 response in relevant cell types. Whether these discrepancies are due to HDAg expression  
9 levels or the use of non-transformed vs. transformed character of hepatocytes remains to be  
10 determined. Using stable cell lines or AAV vectors, we also observed that L-HDAg and S-HDAg  
11 are exclusively located in the nucleus in the absence of HDV RNAs consistent with previous  
12 reports [44]. This reinforces the hypothesis that the transport of HDV proteins to the  
13 cytoplasm requires their association to HDV RNAs.  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24

25 Since type I IFNs decrease both synthesis and stability of HBV RNAs [8, 45], it was suggested  
26 that some HDV-induced ISGs might be responsible for the interference of HDV on HBV  
27 replication [46]. Hence, TRIM22, which is up-regulated upon HDV-infection, exhibited an  
28 antiviral activity against HBV by acting as a transcriptional repressor [47]. DDX60, a  
29 cytoplasmic RNA helicase, which functions as a cell-type specific sentinel for recognition and  
30 degradation of viral RNAs, also up-regulated upon HDV infection, promotes the degradation  
31 of HBV RNAs [48]. Similarly, ISG20, an exo-ribonuclease, induces the degradation of HBV RNAs  
32 [45] through recognition of m6A modifications on the epsilon stem loop [49]. Here, using  
33 chemical and genetic approaches we show that the HDV-induced ISGs are only partially  
34 responsible for the interference of HDV on HBV since abrogation of the HDV-induced IFN  
35 response did not fully revert this phenomenon. Along with these experiments, we confirm  
36 that MDA5, but not RIG-I, through IRF3, is involved in HDV recognition [30]. We also show that  
37 the HDV-induced IFN response has a minor effect on HDV replication itself since the kinetics  
38 of HDV RNAs and proteins appearance/decrease are very similar in dHepaRG-Cas9-RIG<sub>KO</sub> and  
39 dHepaRG-Cas9-MDA5<sub>KO</sub> cells. These data suggest that the ISGs involved in the antiviral effect  
40 observed against HDV in the context of the clinical use of Peg-IFN alpha as well as *in vitro* [50],  
41 might not be among the 73 genes of the HDV signature we have identified in this work. The  
42 data also strongly suggest that the synthesis of L-HDAg, rather than an innate response of  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 hepatocyte, is more likely responsible for the natural decline of HDV replication observed *in*  
2 *vitro*.  
3  
4

5 The comparable levels of cccDNA in the different groups of mice (co-infection versus super-  
6 infection) ruled out that the interference in the co-infection setting was due to cell entry  
7 competition. In contrast, we found that the levels of HBV RNAs (and all subsequent HBV  
8 replication markers) were markedly decreased in the presence of HDV/HDAg suggesting an  
9 inhibition of HBV RNA transcription and/or an acceleration of HBV RNA decay. Previous  
10 studies using an overexpression system suggested that both forms of HDAg might inhibit HBV  
11 replication by repressing the HBV enhancer activity [26]. Here, we extended the finding in an  
12 infection setting with a nascent HBV RNA assay approach in the context of HDV co-infection  
13 or HDAg expression. The mechanism by which HDV/HDAg affects HBV RNA production is still  
14 unclear. Indeed, in the presence of HDV, we found no major modification of the amounts of  
15 the RNA Pol-II, HBc or acetylated histone H3 (H3K27) associated to cccDNA. We also did not  
16 observe significant differences in the in the pool of total and phosphorylated (S2 and S5) RNA  
17 Pol-II associated to cccDNA. Because analysis of epigenetic modifications at targeted positions  
18 in cccDNA is currently not possible, these results do not exclude that HDAg may directly or  
19 indirectly repress HBV RNA synthesis. Alternatively, it is possible that rather than directly  
20 inhibiting HBV RNAs transcription per se, HDV/HDAg might act by rapidly affecting the stability  
21 of nascent HBV RNAs. Following RNA stability assays, we indeed observed a faster decay of  
22 HBV RNAs upon HDV infection/HDAg expression. By performing RNA immunoprecipitation  
23 assays, we showed that both S-HDAg and L-HDAg proteins are associated to the HBV RNAs.  
24 Preliminary results using UV cross-linking suggest that the interaction might be direct. This  
25 should be confirmed by biochemical approaches to identify and narrow down the binding site  
26 of HDAg on HBV RNAs as well as determined whether HDAg binds as multimers as it does with  
27 HDV RNAs [51-53]. Association of HDAg to HBV RNAs should be also tested in liver biopsies  
28 from chronically HBV/HDV infected patients for which no viral interference is observed [23].  
29 As HDAg is a typical RNA binding protein [54] one could hypothesize that it might non-  
30 specifically bind to any RNAs or even DNAs [53]. However, it was already suggested that  
31 interactions of HDAg with cellular RNAs was more specific than expected because only the  
32 GSTP1 mRNA was recovered as potential RNA binder to HDAg after a SELEX [41]. Here we  
33 could not see any association of HDAg to the *PRNP* transcript but further genome wide  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 analyses (RIP-seq) should be performed to determine if HDAg may also associate with cellular  
2 RNAs and thereby possibly induce pathogenesis.

3  
4 It is tempting to speculate that the association of HDAg to HBV RNAs could contribute to/favor  
5 their degradation. The mechanism underlying how HDAg association to HBV RNAs may induce  
6 their degradation will be investigated. Several mechanisms controlling HBV RNA stability were  
7 recently uncovered. For instance, m6A modifications induced within the 3' epsilon stem loop  
8 of all HBV transcripts controls their stability [35] and ISG20 was shown to be the exonuclease  
9 responsible for HBV RNAs degradation [45]. We excluded such a mechanism by evidencing  
10 interference of HDV on HBV even when the m6A site on the epsilon loop of HBV RNAs was  
11 mutated. Extensive mixed tailing of viral RNAs generated via a mechanism exploiting the  
12 TENT4–ZCCHC14 complex was discovered (TENT4 enzymes generate 'mixed tails' of diverse  
13 nucleotides at 3' ends of RNAs via non-templated nucleotide addition to protect messenger  
14 RNAs from de-adenylation) [55, 56] and RG7834 was identified as a molecule inhibiting  
15 TENT4A/B and thereby inducing HBV RNAs degradation [33]. Even though, we did not observe  
16 any shift in the migration of HBV RNAs in the presence of HDV (that would be a reflection of  
17 the shorter polyA tails) contrary to what is observed in cells treated with RG7834, this  
18 mechanism of HBV RNAs destabilization should be further investigated in the context of HDV  
19 interference on HBV.  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35

36 While IFN-dependent interference of one virus with another is commonly observed with  
37 respiratory viruses [57], very few IFN-independent mechanisms of viral interference have  
38 been described especially when considering a satellite virus and its helper virus. Among them,  
39 the AAV2 Rep68 protein can specifically bind to the double-stranded herpes simplex virus 1  
40 (HSV-1) genome and inhibit its replication [58, 59]. To our knowledge, we describe here a new  
41 mechanism of viral interference, in which the proteins of a satellite virus can influence viral  
42 RNA production of its helper virus.  
43  
44  
45  
46  
47  
48  
49

50 Considering that we found no impact of HBV on the level and kinetics of intracellular HDV  
51 replication, it remains to be determined why the mechanisms behind the interference of HDV  
52 on HBV have been selected. Indeed, a decrease in HBsAg, which is required for HDV secretion,  
53 might be considered counter-productive for HDV. However, it should be noticed that the HDV-  
54 induced decrease in HBV is limited (rarely more than 50-60% reduction of HBV RNAs after 13  
55 days of co-infection). This might be because HDAg may bind to HBV RNAs with low affinity  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 compared to binding to HDV RNAs and HBsAg is produced in large excess upon HBV infection.  
2 Finally, infectious HDV particles can be also produced in HBV non-replicating cells producing  
3 HBsAg from integrated HBV DNA [60] suggesting that chronic HDV infection could persist even  
4 when HBV replication is suppressed.  
5

6  
7 To conclude, our data indicate that HDV interferes with HBV through both IFN-dependent and  
8 IFN-independent mechanisms affecting HBV RNAs metabolism. We therefore provide here  
9 important observations that could pave the way to the development of new therapeutic  
10 strategies against HBV by mimicking and/or increasing the effect of HDV on HBV RNAs for  
11 instance.  
12  
13  
14  
15  
16  
17

## 18 **Methods**

19 See supplementary file.  
20  
21  
22  
23  
24

## 25 **References**

26 Author names in bold designate shared co-first authorship.  
27  
28  
29  
30

- 31 [1] Newbold JE, Xin H, Tencza M, Sherman G, Dean J, Bowden S, et al. The covalently closed  
32 duplex form of the hepadnavirus genome exists in situ as a heterogeneous population of viral  
33 minichromosomes. *J Virol* 1995;69:3350-3357.  
34 [2] Bock CT, Schranz P, Schroder CH, Zentgraf H. Hepatitis B virus genome is organized into  
35 nucleosomes in the nucleus of the infected cell. *Virus Genes* 1994;8:215-229.  
36 [3] Bock CT, Schwinn S, Locarnini S, Fyfe J, Manns MP, Trautwein C, et al. Structural  
37 organization of the hepatitis B virus minichromosome. *Journal of molecular biology*  
38 2001;307:183-196.  
39 [4] Belloni L, Pollicino T, De Nicola F, Guerrieri F, Raffa G, Fanciulli M, et al. Nuclear HBx  
40 binds the HBV minichromosome and modifies the epigenetic regulation of cccDNA function.  
41 *Proc Natl Acad Sci U S A* 2009;106:19975-19979.  
42 [5] **Lucifora J, Arzberger S**, Durantel D, Belloni L, Strubin M, Levrero M, et al. Hepatitis B  
43 virus X protein is essential to initiate and maintain virus replication after infection. *J Hepatol*  
44 2011;55:996-1003.  
45 [6] Pollicino T, Belloni L, Raffa G, Pediconi N, Squadrito G, Raimondo G, et al. Hepatitis B  
46 virus replication is regulated by the acetylation status of hepatitis B virus cccDNA-bound H3  
47 and H4 histones. *Gastroenterology* 2006;130:823-837.  
48 [7] Benhenda S, **Ducroux A, Riviere L**, Sobhian B, Ward MD, Dion S, et al. Methyltransferase PRMT1 is a binding partner of HBx and a negative regulator of hepatitis B  
49 virus transcription. *J Virol* 2013;87:4360-4371.  
50 [8] Belloni L, Allweiss L, Guerrieri F, Pediconi N, Volz T, Pollicino T, et al. IFN-alpha inhibits  
51 HBV transcription and replication in cell culture and in humanized mice by targeting the  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

epigenetic regulation of the nuclear cccDNA minichromosome. *J Clin Invest* 2012;122:529-537.

[9] Rizzetto M, Canese MG, Gerin JL, London WT, Sly DL, Purcell RH. Transmission of the hepatitis B virus-associated delta antigen to chimpanzees. *J Infect Dis* 1980;141:590-602.

[10] Gudima S, Wu SY, Chiang CM, Moraleta G, Taylor J. Origin of hepatitis delta virus mRNA. *J Virol* 2000;74:7204-7210.

[11] Hsieh SY, Chao M, Coates L, Taylor J. Hepatitis delta virus genome replication: a polyadenylated mRNA for delta antigen. *J Virol* 1990;64:3192-3198.

[12] Lucifora J, Delphin M. Current knowledge on Hepatitis Delta Virus replication. *Antiviral Res* 2020;179:104812.

[13] Hadziyannis SJ, Sherman M, Lieberman HM, Shafritz DA. Liver disease activity and hepatitis B virus replication in chronic delta antigen-positive hepatitis B virus carriers. *Hepatology* 1985;5:544-547.

[14] Negro F, Korba BE, Forzani B, Baroudy BM, Brown TL, Gerin JL, et al. Hepatitis delta virus (HDV) and woodchuck hepatitis virus (WHV) nucleic acids in tissues of HDV-infected chronic WHV carrier woodchucks. *J Virol* 1989;63:1612-1618.

[15] **Lutgehetmann M, Mancke LV**, Volz T, Helbig M, Allweiss L, Bornscheuer T, et al. Humanized chimeric uPA mouse model for the study of hepatitis B and D virus interactions and preclinical drug evaluation. *Hepatology* 2012;55:685-694.

[16] Pollicino T, Raffa G, Santantonio T, Gaeta GB, Iannello G, Alibrandi A, et al. Replicative and transcriptional activities of hepatitis B virus in patients coinfecting with hepatitis B and hepatitis delta viruses. *J Virol* 2011;85:432-439.

[17] Arribas JR, Gonzalez-Garcia JJ, Lorenzo A, Montero D, Ladron de Guevara C, Montes M, et al. Single (B or C), dual (BC or BD) and triple (BCD) viral hepatitis in HIV-infected patients in Madrid, Spain. *Aids* 2005;19:1361-1365.

[18] Colombo P, Di Blasi F, Magrin S, Fabiano C, Di Marco V, D'Amelio L, et al. Smouldering hepatitis B virus replication in patients with chronic liver disease and hepatitis delta virus superinfection. *J Hepatol* 1991;12:64-69.

[19] Lee SD, Wang JY, Wu JC, Tsai YT, Lo KJ, Lai KH, et al. Hepatitis D virus (delta agent) superinfection in an endemic area of hepatitis B infection: immunopathologic and serologic findings. *Scand J Infect Dis* 1987;19:173-177.

[20] Pastore G, Monno L, Santantonio T, Angarano G, Milella M, Giannelli A, et al. Hepatitis B virus clearance from serum and liver after acute hepatitis delta virus superinfection in chronic HBsAg carriers. *J Med Virol* 1990;31:284-290.

[21] Sagnelli E, Felaco FM, Rapicetta M, Stroffolini T, Petruzzello A, Annella T, et al. Interaction between HDV and HBV infection in HBsAg-chronic carriers. *Infection* 1991;19:155-158.

[22] Schaper M, Rodriguez-Frias F, Jardi R, Tabernero D, Homs M, Ruiz G, et al. Quantitative longitudinal evaluations of hepatitis delta virus RNA and hepatitis B virus DNA shows a dynamic, complex replicative profile in chronic hepatitis B and D. *J Hepatol* 2010;52:658-664.

[23] Lutterkort GL, Wranke A, Hengst J, Yurdaydin C, Stift J, Bremer B, et al. Viral dominance patterns in chronic hepatitis delta determine early response to interferon alpha therapy. *J Viral Hepat* 2018;25:1384-1394.

[24] Alfaiate D, Lucifora J, Abeywickrama-Samarakoon N, Michelet M, Testoni B, Cortay JC, et al. HDV RNA replication is associated with HBV repression and interferon-stimulated genes induction in super-infected hepatocytes. *Antiviral Res* 2016;136:19-31.

- 1 [25] Wu JC, Chen PJ, Kuo MY, Lee SD, Chen DS, Ting LP. Production of hepatitis delta virus  
2 and suppression of helper hepatitis B virus in a human hepatoma cell line. *J Virol*  
3 1991;65:1099-1104.
- 4 [26] Williams V, Brichler S, Radjef N, Lebon P, Goffard A, Hober D, et al. Hepatitis delta virus  
5 proteins repress hepatitis B virus enhancers and activate the alpha/beta interferon-inducible  
6 MxA gene. *J Gen Virol* 2009;90:2759-2767.
- 7 [27] Giersch K, Allweiss L, Volz T, Helbig M, Bierwolf J, Lohse AW, et al. Hepatitis Delta co-  
8 infection in humanized mice leads to pronounced induction of innate immune responses in  
9 comparison to HBV mono-infection. *J Hepatol* 2015;63:346-353.
- 10 [28] Niu C, Li L, Daffis S, Lucifora J, Bonnin M, Maadadi S, et al. Toll-like receptor 7 agonist  
11 GS-9620 induces prolonged inhibition of HBV via a type I interferon-dependent mechanism. *J*  
12 *Hepatol* 2018;68:922-931.
- 13 [29] Du Z, Whitt MA, Baumann J, Garner JM, Morton CL, Davidoff AM, et al. Inhibition of  
14 type I interferon-mediated antiviral action in human glioma cells by the IKK inhibitors BMS-  
15 345541 and TPCA-1. *Journal of interferon & cytokine research : the official journal of the*  
16 *International Society for Interferon and Cytokine Research* 2012;32:368-377.
- 17 [30] Zhang Z, Filzmayer C, Ni Y, Sultmann H, Mutz P, Hiet MS, et al. Hepatitis D virus  
18 replication is sensed by MDA5 and induces IFN-beta/lambda responses in hepatocytes. *J*  
19 *Hepatol* 2018.
- 20 [31] Chang FL, Chen PJ, Tu SJ, Wang CJ, Chen DS. The large form of hepatitis delta antigen  
21 is crucial for assembly of hepatitis delta virus. *Proc Natl Acad Sci U S A* 1991;88:8490-8494.
- 22 [32] Modahl LE, Lai MM. The large delta antigen of hepatitis delta virus potently inhibits  
23 genomic but not antigenomic RNA synthesis: a mechanism enabling initiation of viral  
24 replication. *J Virol* 2000;74:7375-7380.
- 25 [33] **Mueller H, Lopez A**, Tropberger P, Wildum S, Schmalzer J, Pedersen L, et al. PAPD5/7  
26 Are Host Factors That Are Required for Hepatitis B Virus RNA Stabilization. *Hepatology* 2018.
- 27 [34] Tan G, Song H, Xu F, Cheng G. When Hepatitis B Virus Meets Interferons. *Front*  
28 *Microbiol* 2018;9:1611.
- 29 [35] **Imam H, Khan M**, Gokhale NS, McIntyre ABR, Kim GW, Jang JY, et al. N6-  
30 methyladenosine modification of hepatitis B virus RNA differentially regulates the viral life  
31 cycle. *Proc Natl Acad Sci U S A* 2018;115:8829-8834.
- 32 [36] Lukavsky PJ. Structure and function of HCV IRES domains. *Virus Res* 2009;139:166-171.
- 33 [37] O'Leary VB, Dolly OJ, Hoschl C, Cerna M, Ovsepian SV. Unpacking Pandora From Its Box:  
34 Deciphering the Molecular Basis of the SARS-CoV-2 Coronavirus. *Int J Mol Sci* 2020;22.
- 35 [38] Winer BY, **Shirvani-Dastgerdi E, Bram Y**, Sellau J, Low BE, Johnson H, et al. Preclinical  
36 assessment of antiviral combination therapy in a genetically humanized mouse model for  
37 hepatitis delta virus infection. *Sci Transl Med* 2018;10.
- 38 [39] **He W, Ren B**, Mao F, Jing Z, Li Y, Liu Y, et al. Hepatitis D Virus Infection of Mice  
39 Expressing Human Sodium Taurocholate Co-transporting Polypeptide. *PLoS Pathog*  
40 2015;11:e1004840.
- 41 [40] **Suarez-Amaran L, Usai C**, Di Scala M, Godoy C, Ni Y, Hommel M, et al. A new HDV  
42 mouse model identifies mitochondrial antiviral signaling protein (MAVS) as a key player in IFN-  
43 beta induction. *J Hepatol* 2017.
- 44 [41] **Chen M, Du D**, Zheng W, Liao M, Zhang L, Liang G, et al. Small hepatitis delta antigen  
45 selectively binds to target mRNA in hepatic cells: a potential mechanism by which hepatitis D  
46 virus downregulates glutathione S-transferase P1 and induces liver injury and  
47 hepatocarcinogenesis. *Biochem Cell Biol* 2019;97:130-139.
- 48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

- 1 [42] Abe H, Hayes CN, Ochi H, Maekawa T, Tsuge M, Miki D, et al. IL28 variation affects  
2 expression of interferon stimulated genes and peg-interferon and ribavirin therapy. *J Hepatol*  
3 2011;54:1094-1101.
- 4 [43] Honda M, Sakai A, Yamashita T, Nakamoto Y, Mizukoshi E, Sakai Y, et al. Hepatic ISG  
5 expression is associated with genetic variation in interleukin 28B and the outcome of IFN  
6 therapy for chronic hepatitis C. *Gastroenterology* 2010;139:499-509.
- 7 [44] Tavanez JP, Cunha C, Silva MC, David E, Monjardino J, Carmo-Fonseca M. Hepatitis  
8 delta virus ribonucleoproteins shuttle between the nucleus and the cytoplasm. *RNA*  
9 2002;8:637-646.
- 10 [45] Liu Y, Nie H, Mao R, Mitra B, Cai D, Yan R, et al. Interferon-inducible ribonuclease ISG20  
11 inhibits hepatitis B virus replication through directly binding to the epsilon stem-loop structure  
12 of viral RNA. *PLoS Pathog* 2017;13:e1006296.
- 13 [46] Zhang Z, Urban S. Interplay between Hepatitis D Virus and the Interferon Response.  
14 *Viruses* 2020;12.
- 15 [47] **Gao B, Duan Z**, Xu W, Xiong S. Tripartite motif-containing 22 inhibits the activity of  
16 hepatitis B virus core promoter, which is dependent on nuclear-located RING domain.  
17 *Hepatology* 2009;50:424-433.
- 18 [48] **Kouwaki T, Fukushima Y**, Daito T, Sanada T, Yamamoto N, Mifsud EJ, et al. Extracellular  
19 Vesicles Including Exosomes Regulate Innate Immune Responses to Hepatitis B Virus Infection.  
20 *Front Immunol* 2016;7:335.
- 21 [49] Imam H, Kim GW, Mir SA, Khan M, Siddiqui A. Interferon-stimulated gene 20 (ISG20)  
22 selectively degrades N6-methyladenosine modified Hepatitis B Virus transcripts. *PLoS Pathog*  
23 2020;16:e1008338.
- 24 [50] **Michelet M, Alfaiate D, Charde B**, Pons C, Faure-Dupuy S, Engleitner T, et al. Inducers  
25 of the NF-kappaB pathways impair hepatitis delta virus replication and strongly decrease  
26 progeny infectivity in vitro. *JHEP Rep* 2022;4:100415.
- 27 [51] Zuccola HJ, Rozzelle JE, Lemon SM, Erickson BW, Hogle JM. Structural basis of the  
28 oligomerization of hepatitis delta antigen. *Structure* 1998;6:821-830.
- 29 [52] Cornillez-Ty CT, Lazinski DW. Determination of the multimerization state of the  
30 hepatitis delta virus antigens in vivo. *J Virol* 2003;77:10314-10326.
- 31 [53] Alves C, Cheng H, Roder H, Taylor J. Intrinsic disorder and oligomerization of the  
32 hepatitis delta virus antigen. *Virology* 2010;407:333-340.
- 33 [54] Daigh LH, Griffin BL, Soroush A, Mamedov MR, Casey JL. Arginine-rich motifs are not  
34 required for hepatitis delta virus RNA binding activity of the hepatitis delta antigen. *J Virol*  
35 2013;87:8665-8674.
- 36 [55] Hyrina A, Jones C, Chen D, Clarkson S, Cochran N, Feucht P, et al. A Genome-wide  
37 CRISPR Screen Identifies ZCCHC14 as a Host Factor Required for Hepatitis B Surface Antigen  
38 Production. *Cell reports* 2019;29:2970-2978 e2976.
- 39 [56] **Kim D, Lee YS, Jung SJ, Yeo J**, Seo JJ, Lee YY, et al. Viral hijacking of the TENT4-ZCCHC14  
40 complex protects viral RNAs via mixed tailing. *Nature structural & molecular biology*  
41 2020;27:581-588.
- 42 [57] Essaidi-Laziosi M, Geiser J, Huang S, Constant S, Kaiser L, Tapparel C. Interferon-  
43 Dependent and Respiratory Virus-Specific Interference in Dual Infections of Airway Epithelia.  
44 *Scientific reports* 2020;10:10246.
- 45 [58] **Glaser DL, Seyffert M**, Strasser R, Franchini M, Laimbacher AS, Dresch C, et al.  
46 Inhibition of herpes simplex virus type 1 replication by adeno-associated virus rep proteins  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

depends on their combined DNA-binding and ATPase/helicase activities. J Virol 2010;84:3808-3824.

[59] Seyffert M, Glauser DL, Tobler K, Georgiev O, Vogel R, Vogt B, et al. Adeno-Associated Virus Type 2 Rep68 Can Bind to Consensus Rep-Binding Sites on the Herpes Simplex Virus 1 Genome. J Virol 2015;89:11150-11158.

[60] Freitas N, Cunha C, Menne S, Gudima SO. Envelope proteins derived from naturally integrated hepatitis B virus DNA support assembly and release of infectious hepatitis delta virus particles. J Virol 2014;88:5742-5754.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

## Figure legends

1  
2  
3  
4 **Figure 1. HDV reduces the levels of HBV RNAs, secreted HBV antigens and DNA but not**  
5 **cccDNA *in vivo* and *in vitro*.** (A, B) Differentiated HepaRG cells (dHepaRG, at least 3 batches  
6 of differentiation) or primary human hepatocytes (PHH, 3 donors) were infected with HBV  
7 alone or with HBV and HDV at multiplicity of infection of 500 and 50 vge/cell respectively.  
8 Thirteen days post-infection, the levels of intracellular HBV RNAs were analyzed by RT-qPCR  
9 or Northern blot, the levels of cccDNA by qPCR whereas the levels of secreted HBeAg and  
10 HBsAg were assessed by ELISA. Data were normalized to the “HBV” condition after being  
11 normalized to a housekeeping gene (*PRNP*) in the case of the RT-qPCRs. Results are the mean  
12 +/- SD of three independent experiments each performed with three biological replicates. (C)  
13 Chimeric liver humanized mice (FRG NOD) were infected with HBV alone, with HBV and HDV  
14 or with HBV first and with HDV 4 weeks later. At the indicated weeks post (HBV) infection  
15 (wpi), sera were collected and HBV and HDV viremia were analyzed by qPCR and qRT-PCR  
16 whereas the levels of secreted HBeAg and HBsAg were assessed by ELISA. Twelve wpi, mice  
17 were sacrificed and the levels of intrahepatic total HBV DNAs as well as cccDNA were analyzed  
18 by qPCR respectively and normalized to B-Globin. Results are the mean +/- SEM of 6 to 5 mice  
19 per group. Statistical analyses were performed using Mann-Whitney tests and p values are  
20 indicated (significance when  $p < 0.05$ ).

21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39 **Figure 2. HDV-induced transcriptomic modulations.** Differentiated HepaRG cells (dHepaRG)  
40 or primary human hepatocytes (PHH, 3 donors) were infected with HBV alone, with HDV alone  
41 or with HBV and HDV at multiplicity of infection of 500 and 50 vge/cell respectively or treated  
42 with IFN- $\alpha$  (1000 UI/mL). RNA samples collected at day 6 post-infection or day 1 post  
43 treatment with IFN- $\alpha$  (for PHH and dHepaRG) or at weeks 12 post-HBV infection (8 weeks  
44 post-HDV infection) for mice or from human liver biopsies were analyzed by RNA sequencing.  
45 (A) Pathways activities relative to non-infected conditions are presented for each model. The  
46 color corresponds to the difference in GSEA scores for each model compared to uninfected  
47 control samples. \*nominal p-value  $< 0.05$  (B) ISGs that are significantly different ( $\log_2(\text{Fold}$   
48 Change)  $> 1$ , nominal  $p < 0.05$ ) in the HDV models. In this case the color corresponds to the  
49  $\log_2(\text{Fold Change})$ . ISGs were defined either being included in IFN- $\alpha$  by Molecular Signatures Database  
50 Hallmark gene sets (the same set used for or if they significantly upregulated in the PHHs or  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

HepaRGs by IFN- $\alpha$ ). The genes selected had at least nominal p-values below 0.05 and log<sub>2</sub>(Fold Change) of at least 1 in all three models.

**Figure 3. Inhibition of the HDV-induced IFN response by TPCA-1 partially restores the levels of HBV RNAs and secreted HBV antigens and particles.** Differentiated HepaRG cells were infected with HBV, HDV or with HBV and HDV at multiplicity of infection of 500 (HBV) and 50 (HDV) vge/cell and treated or not with TPCA-1 (1  $\mu$ M). (A) Six days post-infection, the levels of RSAD2 mRNAs, MxA mRNAs, HDV RNAs and HBV RNAs were analyzed by RT-qPCR. (B) Thirteen days post infection, the levels of secreted HBeAg and HBsAg were assessed by ELISA, the levels of secreted HBV DNA by qPCR and the levels of intracellular HBV and HDV RNAs were analyzed by RT-qPCR. In the case of the RT-qPCRs, all the data were normalized to a housekeeping gene (*PRNP*) and in addition to the “non treated HBV” condition for (B). Results are the mean +/- SD of two independent experiments each performed with three biological replicates. Statistical analyses were performed using Mann-Whitney tests and p values are indicated (significance when  $p < 0.05$ ).

**Figure 4. Abrogating the HDV-induced IFN response partially restores levels of HBV RNAs and secreted HBV antigens.** Differentiated HepaRG, HepaRG-Cas9-CTL, HepaRG-Cas9-RIG-I<sub>KO</sub>, HepaRG-Cas9-MDA5<sub>KO</sub> or HepaRG-Cas9-IRF3<sub>KO</sub> cells were infected with HBV and HDV at multiplicity of infection of 500 and 50 vge/cell respectively. (A, B, C) RNA samples collected at day 6 post-infection were analyzed for the levels of (A) HBV and HDV RNAs and (B) RSAD2 mRNAs by RT-qPCR or (C) RNA sequencing. The heat map represents log<sub>2</sub> fold changes without transformation. (D, E, F) Thirteen days post infection, the levels of secreted (D) HBsAg and (E) HBeAg were assessed by ELISA and the levels of (F) intracellular HBV RNAs were analyzed by RT-qPCR. Data were normalized to the “HBV” condition after being normalized to a housekeeping gene (*PRNP*) in the case of the RT-qPCRs except for RSAD2 mRNAs for which data were normalized to *PRNP* mRNA only. (B, D, E, F) Results are the mean +/- SD of three to five independent experiments each performed with three biological replicates. Statistical analyses were performed using Mann-Whitney tests and p values are indicated (significance when  $p < 0.05$ ).

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

**Figure 5. Expression of HDAg alone decreases the levels of HBV RNAs and secreted antigens without inducing an IFN response.** dHepaRG were infected with HBV at a multiplicity of infection of 500 vge/cell. Three days later, cells were infected with HDV at a multiplicity of infection of 50 vge/cell or transduced with AAV-GFP, AAV-SHD or AAV-LHD at the indicated multiplicity of infection (vge/cells). (A) At days 14 post-HBV infection, cells were lysed and the presence of HDAg was assessed by western blot analyses. (B) The levels of intracellular HBV RNAs, HNF4a, RSAD2 and MxA mRNAs were analyzed by RT-qPCR whereas the levels of secreted HBeAg and HBsAg were assessed by ELISA. Data were normalized to the “AAV-GFP 10<sup>3</sup>” condition after being normalized to a housekeeping gene (*PRNP*) in the case of the RT-qPCRs except for RSAD2 and HNF4a mRNAs for which data were normalized to *PRNP* mRNAs only. Results are the mean +/- SD of two independent experiments each performed with three biological replicates. Statistical analyses were performed using Mann-Whitney tests and p values are indicated (significance when p<0.05).

27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

**Figure 6. HDV decreases the synthesis and stability of HBV RNAs.** (A) dHepaRG were infected with HBV at multiplicity of infection of 500 vge/cell with or without HDV at multiplicity of infection of 50 vge/cell. At day 10 post infection with HBV, some cells were treated with RG7834 (1 uM). At day 13 post infection with HBV, cells were collected, RNA extracted and analyzed by Northern Blot. (B) dHepaRG were infected with HBV at multiplicity of infection of 500 vge/cell with or without HDV at multiplicity of infection of 50 vge/cell. At day 3 post infection, some cells were treated with RG7834 (1 uM) or IFN- $\alpha$  (500 IU/mL) for 10 days. At day 13 post infection with HBV, cells were incubated or not with bromo-uridine (BrU, 2 mM) for 2h. As a control, some cells were treated with actinomycin D (Act D, 1 ug/mL) for 1h before incubation with BrU. Cells were then collected, RNAs extracted and the levels of total intracellular HBV RNAs (normalized to *PRNP*) as well as BrU-labeled HBV RNAs (nascent HBV RNAs normalized to the mock) were analyzed by RT-qPCR. Results are the mean +/- SD of two independent experiments performed with 4 biological replicates. (C) dHepaRG were infected with HBV at multiplicity of infection of 500 vge/cell. Three days later cells were either infected by HDV at multiplicity of infection of 50 vge/cell, transduced with the indicated AAV vectors at multiplicity of infection of 5000 vg/cell or treated with RG7834 (1 uM) or IFN- $\alpha$  (500 IU/mL) for 10 days. At day 13 post infection with HBV, cells were incubated or not with bromo-uridine (BrU, 2 mM) for 2h. Cells were then collected, RNAs extracted and the levels of total


1 intracellular HBV RNAs (normalized to *PRNP*) as well as BrU-labeled HBV RNAs (nascent HBV  
2 RNAs normalized to *PRNP*). Results are the mean +/- SD of three independent experiments  
3 performed with 3 biological replicates. (D) Freshly isolated PHH were infected with HBV at  
4 multiplicity of infection of 500 vge/cell with or without HDV at multiplicity of infection of 50  
5 vge/cell. At day 5 post infection with HBV, some cells were treated with RG7834 (1 uM) or IFN-  
6  $\alpha$  (500 IU/mL). At day 7 post infection with HBV, all cells were treated with triptolide (1 uM)  
7 to block RNA synthesis. At the indicated time post-treatment with Triptolide, cells were  
8 collected, RNA extracted and the levels of HBV RNAs were assessed by RT-qPCR analyses.  
9 Results are the mean +/- SD of two independent experiments each performed with 3 biological  
10 replicates. (E) Freshly isolated PHH were infected with HBV at multiplicity of infection of 500  
11 vge/cell. Three days later cells were either infected by HDV at multiplicity of infection of 50  
12 vge/cell, transduced with the indicated AAV vectors at multiplicity of infection of 5000 vg/cell.  
13 At day 7 post infection with HBV, some cells were treated with RG7834 (1 uM). At day 10 post  
14 infection with HBV, all cells were treated with Triptolide (1 uM) to block RNA synthesis. At the  
15 indicated time post-treatment with Triptolide, cells were collected, RNA extracted and the  
16 levels of HBV RNAs were assessed by RT-qPCR analyses. Results are the mean +/- SD of one  
17 experiment performed with 3 biological replicates. Statistical analyses were performed using  
18 Mann-Whitney tests and p values are indicated (significance when  $p < 0.05$ ).

19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37 **Figure 7. HDAg are associated to HBV RNAs in HBV/HDV infected PHH, dHepaRG and HuHep**  
38 **mice.** (A, B, C) Cells pellets from HBV/HDV infected (A) PHH or (B) dHepaRG (9 days post-  
39 infection) or (C) frozen liver from HBV/HDV infected HuHep mice (12 weeks post-infection)  
40 were cross-linked with 1% formaldehyde before immunoprecipitation with the indicated  
41 antibodies (IgG mouse, anti-HBc, anti-RNA Pol-II, pre-immune sera or anti-HDAg). 0.16<sup>e</sup> of the  
42 immunoprecipitated materials (IP) as well as 0.04<sup>e</sup> of the the flowthrough (FT) were analyzed  
43 were by western blot. RNAs were extracted from the 0,28<sup>e</sup> of the immunoprecipitated  
44 materials and the levels of HDV or HBV RNAs associated to the indicated proteins were  
45 analyzed by RT-qPCR. DNAs were extracted from the 0.56<sup>e</sup> of the immunoprecipitated  
46 materials and the levels of cccDNA associated to the indicated proteins were analyzed by  
47 qPCR. Results are the mean +/- SEM of three independent experiments. (D) dHepaRG were  
48 infected with HBV at multiplicity of infection of 500 vge/cell. Four days later, cells were  
49 infected with HDV at multiplicity of infection of 50 vge/cell or transduced with the indicated


AAV vectors at multiplicity of infection of 5000 vg/cell. Eleven days post infection with HBV, cells were cross-linked with formaldehyde before immunoprecipitation with the indicated antibodies (IgG mouse or anti-HDAg). RNAs were extracted from the immunoprecipitated materials and the levels of HBV RNAs were analyzed by RTqPCR. Results are the mean +/- SEM of two independent experiments each performed with two biological replicates.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65


**A - HepaRG**







**B - PHH**











**C - HuHep mice**






**A****B**


**A****B****C****D****E****F**

**A****B**


A




B




C




D




E




**A - PHH**




**B - dHepaRG**



**C - HuHep mice**




**D - dHepaRG**



Biopsy ID	H-number	Ethnicity	Age	Phase	Gender	Log HBV DNA	HbeAg	Anti-HBeAg	ALT	AST	HbsAg	Genotype	Interface_inflam	Lobulaire_inflam	Portale_inflam	confluent_crosis	NASH	METAVIR	Steatosis	Comments
AB.02	Healthies	Caucasian	52	HC	F	NA	NA	NA	24	27	Negative	NA	No	No	No	#N/A	No	F0	No	
AB.04	Healthies	Caucasian	51	HC	M	NA	NA	NA	21	23	Negative	NA	No	Moderate	No	#N/A	No	F0	No	
AB.03	Healthies	Caucasian	55	HC	F	NA	NA	NA	28	28	Negative	NA	No	No	No	#N/A	No	F0	No	
AB.07	Healthies	Caucasian	57	HC	F	NA	NA	NA	24	28	Negative	NA	No	No	No	#N/A	No	F0	No	
AB.01	Healthies	Caucasian	27	HC	M	NA	NA	NA	61	36	Negative	NA	#N/A	Moderate	#N/A	#N/A	No	NA	No	
AB.145	Healthies	Other	28	HC	M	NA	Negative	Negative	33	23	Negative	NA	No	No	No	#N/A	No	NA	No	
AB.146	Healthies	Caucasian	63	HC	M	NA	NA	NA	28	23	Negative	NA	No	No	No	#N/A	No	NA	No	
AB.05	Healthies	Caucasian	49	HC	M	NA	NA	NA	NA	NA	Negative	NA	#N/A	#N/A	#N/A	#N/A	No	NA	No	
AB.06	Healthies	Other	43	HC	M	NA	NA	NA	NA	NA	Negative	NA	#N/A	#N/A	#N/A	#N/A	No	NA	No	
AB.23	F3/F4	Asian	19	F34	M	4,245	Negative	Positive	56	45		C	Mild/Moderate	<2 foci	Moderate/Marked	No	No	4	No	
AB.18	F3/F5	Asian	48	F34	M	8,052	Positive	Negative	80	128		ND	Moderate	2-4 foci	Moderate/Marked	No	No	4	No	
AB.45	F3/F6	Asian	32	F34	F	3,374	Negative	Positive	122	80		C	Moderate	2-4 foci	Moderate/Marked	No	No	4	No	
AB.59	F3/F7	Caucasian	24	F34	M	5,23	Positive	Negative	142	84		ND	Moderate	5-10 foci	Moderate/Marked	No	No	4	No	
AB.51	F3/F8	Caucasian	37	F34	M	9,055	Negative	Positive	204	99		D	Mild/Moderate	<2 foci	Moderate	No	No	4	Yes	
AB.138	HBV/HDV	African	43	HBV/HDV	F	4,08	Negative	Positive	36	38		E	Mild/Moderate	<2 foci	Moderate/Marked	No	No	3	No	severe fibrosis or cirrhosis, no treatment
AB.140	HBV/HDV	Caucasian	44	HBV/HDV	M	<3	Negative	Positive	112	88		ND	Yes	Yes	#N/A	#N/A	No	F4	No	history of iv drug use, had cleared HCV, has liver cirrhosis, no treatment
AB.142	HBV/HDV	African	28	HBV/HDV	M	1,39	Negative	Positive	53	57		ND	#N/A	#N/A	#N/A	#N/A	No	#N/A	No	severe fibrosis, macronocular cirrhosis
AB.143	HBV/HDV	Other	49	HBV/HDV	F	1,65	Negative	Positive	93	48	>150	ND	#N/A	present	moderate	#N/A	No	F2	yes, mild	no therapy
AB.144	HBV/HDV	Other	50	HBV/HDV	M	ND	Negative	Positive	ND	ND	>150	ND	#N/A	present	#N/A	#N/A	No	severe fibrosis	yes, mild	severe fibrosis to cirrhosis, on treatment with tenofivir

Table 1. Patient characteristics linked to the human liver biopsies used for RNA sequencing.

### IFN dependant and independant interference of HDV on HBV



## Highlights

- we define the HDV-induced signature transcriptomic modulations mainly composed of ISGs
- ISGs are upregulated upon HDV infection but not in cells only expressing HDAg alone
- HDV interferes with HBV through both IFN-dependent and IFN-independent mechanisms
- HDV infection and HDAg expression decrease the levels of nascent HBV RNAs and accelerated the decay of HBV RNA
- HDAg are associated with HBV RNAs



[Click here to access/download](#)

**Supplementary material**

JHEPAT-D-22-00233 - revised 221212 - sup.docx

